Library Open Repository
Drug evaluation: VX-702, a MAP kinase inhibitor for rheumatoid arthritis and acute coronary syndrome
Ding, C (2006) Drug evaluation: VX-702, a MAP kinase inhibitor for rheumatoid arthritis and acute coronary syndrome. Current Opinion in Investigational Drugs, 7 (11). pp. 1020-1025. ISSN 1472-4472
vx-702.pdf | Download (221kB)
Available under University of Tasmania Standard License.
Vertex Pharmaceuticals Inc, in collaboration with Kissei Pharmaceutical Co Ltd, is developing VX-702, one of a series of second-generation, orally active p38 MAP kinase inhibitors, for the potential treatment of inflammation, rheumatoid arthritis and cardiovascular diseases. In June 2005, a phase II clinical trial of VX-702 was initiated in rheumatoid arthritis. In July 2006, Vertex was planning to file an IND in the second half of 2006.
|Journal or Publication Title:||Current Opinion in Investigational Drugs|
|Page Range:||pp. 1020-1025|
|Additional Information:||restricted - published by Thompson|
|Date Deposited:||28 Mar 2008 00:47|
|Last Modified:||18 Nov 2014 03:32|
|Item Statistics:||View statistics for this item|
Actions (login required)
|Item Control Page|